Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Botox-maker Allergan Inc.announced the second-quarter profit early Friday

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Europe’s Tissue Industry Supports Millions of...

New data highlights the sector’s economic contribution and essential...

Personalized Medicine Advancing Targeted Treatment Path

A comprehensive analysis of how genomic insights, biomarker research, and data-driven precision therapies are transforming the traditional one-size-fits-all medical model into highly individualized patient care.

Beyond the Waitlist: How a Single...

For many families, the path to an autism diagnosis...
Research Insight
Botox-maker Allergan Inc. announced the second-quarter profit early Friday, the figures were substantially higher, attributable in part to the company’s cost-cutting measures.

Botox-maker Allergan Inc. announced the second-quarter profit early Friday, the figures were substantially higher, attributable in part to the company’s cost-cutting measures.

Allergan registered its second-quarter earnings rose to $176.1 million from $143.4 million in the year-earlier period.

Excluding various items, Allergan would have posted adjusted earnings of 75 cents a share compared to the year-earlier 63 cents.

Analysts polled by FactSet were expecting earnings of 67 cents a share, on average.

Revenue for the quarter slipped to $1.13 billion from $1.17 billion. Excluding the impact of a strong U.S. dollar overseas, sales would have been up 2.2%.

The Irvine, Calif.-based company also issued its financial forecast. Allergan now sees adjusted earnings of 67 cents to 69 cents a share for the third quarter and $2.71 to $2.75 a share for the full year.

Full-year sales should come in between $4.2 billion and $4.3 billion, while third-quarter sales are pegged at $1.05 billion to $1.1 billion.

 

MEDICAL FAIR ASIA 2026

Latest stories

Related stories

Personalized Medicine Advancing Targeted Treatment Path

A comprehensive analysis of how genomic insights, biomarker research, and data-driven precision therapies are transforming the traditional one-size-fits-all medical model into highly individualized patient care.

Medical Imaging Innovation Improving Diagnostic Accuracy

The rapid evolution of high-resolution sensors and intelligent algorithmic...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »